InflaRx (NASDAQ:IFRX) Short Interest Up 37.9% in December

InflaRx (NASDAQ:IFRX) was the recipient of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 216,500 shares, an increase of 37.9% from the November 30th total of 157,000 shares. Based on an average trading volume of 243,600 shares, the short-interest ratio is presently 0.9 days.

InflaRx Stock Up 1.9 %

IFRX stock traded up $0.05 during midday trading on Monday, reaching $2.64. 215,593 shares of the company’s stock traded hands, compared to its average volume of 187,703. The firm’s fifty day moving average price is $2.03 and its 200-day moving average price is $1.71. InflaRx has a 52 week low of $1.16 and a 52 week high of $2.82. The company has a market cap of $155.44 million, a price-to-earnings ratio of -2.44 and a beta of 1.67.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of InflaRx in a research report on Friday, December 20th.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.